Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 21, 2004

Primary Completion Date

March 1, 2025

Study Completion Date

December 1, 2025

Conditions

Malignant Supratentorial NeoplasmRecurrent GlioblastomaRecurrent Gliosarcoma

Interventions

DRUG

Lonafarnib

Given PO

DRUG

Temozolomide

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER